HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sampson, M. J. Articles by Carrier, M. J. Search for Related Content PubMed PubMed Citation Articles by Sampson, M. J. Articles by Carrier, M. J. Social Bookmarking                What's this?

Plasma F₂ Isoprostanes

Direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes

¹ Bertram Diabetes Research Unit, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, U.K.
² William Harvey Research Institute, St. Bartholomews Hospital, London, U.K.
³ Institute of Food Research, Norwich Research Park, Colney, Norwich, U.K.

	ABSTRACT

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
OBJECTIVES—Acute hyperglycemia in type 2 diabetes increases the generation of plasma 8-epi-prostaglandin F₂ (8-epi-PGF₂) isoprostane, a sensitive direct marker of in vivo free radical oxidative damage to membrane phospholipids.

RESEARCH DESIGN AND METHODS—A total of 21 patients with type 2 diabetes underwent an oral 75-g glucose tolerance test. Plasma 8-epi-PGF₂ isoprostane concentrations (by gas chromatography [GC]/mass spectrometry [MS]), intralymphocyte reduced-to-oxidized glutathione ratios, and plasma total antioxidant capacity were measured at baseline and 90 min after glucose loading.

RESULTS—Plasma 8-epi-PGF₂ isoprostane concentrations rose significantly (P=0. 010) from 0.241± 0.1 to 0.326± 0.17 ng/l after 90 min. Intracellular oxidative balance and plasma antioxidant capacity did not change in either group.

CONCLUSIONS—Plasma concentrations of 8-epi-PGF₂ isoprostane increase during acute hyperglycemia in type 2 diabetes, providing direct evidence of free radical–mediated oxidative damage and demonstrating a pathway for an association between acute rather than fasting hyperglycemia and macrovascular risk in type 2 diabetes.

Abbreviations: ABTS, 2,2-azino-bis-3-ethylbensthiazoline-6-sulfonic acid • BHT, butylated hydroxytoluene • 8-epi-PGF₂, 8-epi-prostaglandin F₂ • GC, gas chromatography • GSH, glutathione • MS, mass spectrometry • TAOS, total antioxidant status

	INTRODUCTION

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Acute hyperglycemia after a meal or glucose load may be an independent predictor of vascular event rates in type 2 diabetes or impaired glucose tolerance (1–4). One possible mechanism for such a relationship is increased generation of reactive oxygen species during acute hyperglycemia, leading to acute oxidative damage to the vascular endothelium, cell membranes, and lipoprotein components (5).

It has proven difficult to detect increased plasma free radical generation in human diabetes using, for example, electron spin resonance methods (6), and the usefulness of other surrogate markers of oxidative stress has been questioned (7). The F₂ isoprostanes appear to be the best available marker of lipid peroxidation in vivo (8). These stable eicosanoids are produced by the enzyme-independent free radical oxidation of arachidonic acid in membrane phospholipids and lipoproteins and are generated in conditions of increased oxidative stress in animal and human models (8–10). Plasma and urine concentrations of F₂ isoprostanes are increased in type 2 diabetes (11,12), in direct relationship to measures of chronic hyperglycemia (12). It is unknown whether acute hyperglycemia influences F₂ isoprostane generation in type 2 diabetes.

We hypothesized that acute hyperglycemia after a glucose load in people with type 2 diabetes would lead to acutely increased generation of plasma F₂ isoprostanes, and that this would suggest one possible pathway between acute hyperglycemia, associated free radical damage, and macrovascular disease in type 2 diabetes.

	RESEARCH DESIGN AND METHODS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Patient selection
After local ethical committee approval and after obtaining written informed consent, we studied 21 patients with type 2 diabetes. Patients were recruited from the Bertram Diabetes Center, Norwich, U.K. (a secondary care diabetes facility), or from local primary care services if they were nonsmokers aged between 40 and 70 years and treated with diet or oral hypoglycemic agents alone. Patients were considered to have type 2 diabetes if they had been diagnosed after the age of 40 years, had no history of ketosis, and had stable glycemic control on diet or oral hypoglycemic agents for at least 6 months. Patients with clinical evidence of coronary artery disease (history of previous myocardial infarction or angina) and those receiving insulin were excluded. Patients with microalbuminuria (defined as an elevated urine albumin-to-creatinine ratio >2.5 for men and >3.5 for women) or macroproteinuria (defined as albustix-positive proteinuria) were excluded. Patients omitted all oral hypoglycemic agents or other medication on the morning of testing and fasted for 15 h before glucose tolerance tests were undertaken. All type 2 diabetic patients managed with diet alone had a fasting venous plasma glucose >7.0 mmol/l. Clinical details are shown in Table 1.

Intracellular oxidative balance
The intracellular glutathione (GSH) redox cycle between reduced GSH and oxidized GSH is an effective mechanism in protecting against intracellular oxidative damage because GSH acts as substrate for antioxidant enzymes and as a free radical scavenger, and the ratio of reduced-to-oxidized GSH by mass can be used as an index of intracellular oxidative stress (13). A 15-ml sample of whole blood was collected into EDTA, diluted to twice the original volume with PBS, and layered onto a 15 ml lymphocyte separation medium (ICN Biomedicals, Basingstoke, UK). It was then centrifuged at 390g for 30 min at 20°C. The lymphocyte layer was removed and washed twice with PBS, and the cell pellet was resuspended and an aliquot removed for cell counting. GSH was extracted from the lymphocyte pellet and measured using an enzymatic recycling method (14) modified for an automated biochemistry analyzer (Cobas Mira). This ratio was measured at 0 and 90 min during each glucose tolerance test and expressed as a ratio of reduced to oxidized GSH. The 90-min time point was chosen as being peak hyperglycemia and, by extension, the time point most likely to demonstrate changes in hyperglycemia-associated oxidative stress

Plasma F₂ isoprostane concentrations
The determination of 8-epi-prostaglandin F₂ (8-epi-PGF ₂) was based on previously described methodology (11,15). Peripheral venous blood (10 ml) was collected into polyethylene tubes containing a 3.8% (wt/vol) trisodium citrate solution (blood-to-anticoagulant ratio of 9:1) with indomethacin (as a cyclooxygenase inhibitor) and butylated hydroxytoluene (BHT; as a free radical scavenger) at final concentrations of 14 and 20 µmol/l, respectively. The sample was allowed to stand for 30 min at 4°C to enable complete inhibition of cyclooxygenase enzymes. Platelet-poor plasma was obtained by centrifugation at 1,120g for 15 min at 4°C. The plasma was transferred to a polypropylene screw-cap tube, and BHT was added at a final concentration of 20 µmol/l. The sample was then stored at -80°C until analysis. For determination of plasma total antioxidant status (TAOS), blood (5 ml) was collected in EDTA tubes and centrifuged at 1,120g for 15 min at 4°C. The plasma was transferred to screw-cap polypropylene tubes and stored at -80°C until analysis. Plasma samples were subjected to alkaline hydrolysis for the measurement of total (sum of free plus esterified) 8-epi-PGF₂ by GC/MS. Plasma (0.5 ml) was transferred to a glass tube, followed by the addition of 8-epi-PGF₂-d4 as an internal standard (2 ng in 20 ml ethanol). The sample was hydrolyzed with 1.0 mol/l aqueous potassium hydroxide (0.5 ml) for 30 min at 40°C. Hydrolysis was terminated by the addition of 0.1 mol/l hydrochloric acid (4.25 ml), and the pH of the sample was adjusted to 7.4 using 0.05 mol/l sodium phosphate buffer (4.5 ml). Isolation of 8-epi-PGF was carried out by immunoaffinity extraction of the hydrolyzed plasma. Samples were loaded on an immunoaffinity cartridge (prepared with an anti–8-epi-PGF₂ antiserum) preconditioned with 16 ml sodium phosphate buffer (0.05 mol/l, pH 7.4). The cartridge was washed with water (20 ml) to remove nonretained components, and 8-epi-PGF₂ was eluted using an acetone and water mixture (95:5 dilution, 5.5 ml). The immunoaffinity extraction steps were programmed into an Aspec XL sample processor (Gilson Medical Electronics, Villiers-le-Bel, France) and run automatically. The final eluate from the immunoaffinity extraction was dried under nitrogen and the sample converted to a perfluorobutyl/trimethylsilyl (PFB/TMS) derivative. Samples were analyzed by GC/negative ion chemical ionization/MS using an Autosystem XL GC coupled to a TurboMass MS (Perkin-Elmer, Beaconsfield, U.K.), with ammonia as reagent gas. The GC/MS assay has a limit of detection of 10 pg/ml (28 pmol/l) in plasma, with an intra- and interassay coefficient of variation of 4.4 and 7.6%, respectively. Analysis was performed using selected ion recording of the carboxylate anion [M-181] at m/z 569 for 8-epi-PGF₂ and m/z 573 for 8-epi-PGF-d4. Quantitative determination was based on the peak height ratio of 8-epi-PGF₂ against the internal standard. The isolation of 8-epi-PGF₂ from plasma is based on the specific interaction between 8-epi-PGF₂ and polyclonal anti–8-epi-PGF₂ antibodies, prepared by raising antisera against 8-epi-PGF₂. After derivatization of the immunoextracted material, quantitation of 8-epi-PGF₂ was carried out by stable-isotope dilution GC/MS with selected ion recording. The measurement of 8-epi-PGF₂ provides a direct index of lipid peroxidation on phospholipid membranes in vivo and reflects oxidative processes within this environment. Oxidative stress due to hyperglycemia is associated with the increased generation of oxygen-derived radicals, and it is this change in free radical–mediated oxidation that is measured through the analysis of F₂-isoprostanes. The nature of this assay makes it exceptionally unlikely (if not impossible) that direct interference by plasma glucose or insulin concentrations in vivo can occur; indeed, these types of assays are particularly valuable simply because they are not subject to interference from other constituents present in the assay mix. Plasma concentrations of 8-epi-PGF₂ can be expressed in absolute amounts or normalized to plasma total arachidonic acid. Normalized concentrations of 8-epi-PGF₂ are useful in situations where significant changes in the lipid profile or plasma fatty acids are expected, and they are unlikely to provide further information where intervention is limited to an isolated oral glucose load because even a high-calorie/high–saturated fat meal does not influence postprandial plasma total arachidonic levels (16).

TAOS plasma assay
The total antioxidant status of plasma was determined by its capacity to inhibit the peroxidase-mediated formation of the 2,2-azino-bis-3-ethylbensthiazoline-6-sulfonic acid (ABTS ⁺) radical. In this assay, the relative inhibition of ABTS ⁺ formation in the presence of plasma is proportional to the antioxidant capacity of the sample. Briefly, plasma (2.5 µl) was incubated for 3 min at 37°C in a 96-well plate with a reaction mixture made up of (final concentrations) 20 µl ABTS (20 mmol/l), 20 µl horseradish peroxidase (30 mU/ml), and 37.5 µl PBS (pH 7.4). The reaction was started by the addition of 20 ml hydrogen peroxide (final concentration 0.1 mmol/l), and the increase in absorbance over 6 min was monitored at 405 nm, using a microplate reader (model 12605; Anthos Labtech, Salzburg, Austria). At the end of 6 min, the absorbance due to the accumulation of ABTS ⁺ in the test sample was read along with a control (containing 2.5 µl PBS instead of plasma). The difference in absorbance (control absorbance minus test absorbance), divided by the control absorbance (expressed as a percentage) was used to represent the percentage inhibition of the reaction.

Measurement of lipid fractions
Plasma lipid profiles were measured at time 0 and 90 min during each glucose tolerance test. Lipid profiles were assessed using commercially available kits (Roche) on an automated biochemistry analyzer (Cobas Mira; Roche), with estimation of LDL cholesterol (17).

Statistical analysis
Data are shown as the means ±1 SD, and all variables were normally distributed. Differences in individual variables measured more than twice during glucose tolerance test were analyzed by repeated-measure one-way ANOVA, with paired t tests where a significant difference (P < 0.05) was found. Otherwise, paired t tests were used for paired measurements. Relationships between variables were analyzed by simple linear regression or stepped multiple regression analysis with entry at P < 0.1. Data were analyzed using Apple Macintosh Statview software (1996).

	RESULTS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Clinical details
Clinical details are shown in Table 1. Of the diabetes group, 17 (81%) were taking metformin or a metformin-sulfonylurea combination. Seven patients (33%) were taking gliclazide, either alone or in combination with metformin, and seven (33%) were taking antihypertensive medication (Tables 1 and 2).

View this table: [in this window] [in a new window]   Table 2— Changes in oxidative balance and plasma 8-epi-F2 isoprostane during a glucose tolerance test in 21 subjects with type 2 diabetes

Plasma 8-epi-F₂ isoprostane concentrations in type 2 diabetes
There was a highly significant (P=0.0102) rise in plasma 8-epi-F₂ isoprostane concentrations between baseline and 90 min. There were no significant relationships between baseline plasma 8-epi-F₂ isoprostane concentrations and HbA_1c (r=0.32, P=0.15), fasting plasma glucose (r=0.33, P=0.13), or measures of intracellular oxidative balance and total antioxidant capacity (both P > 0.2). Peak plasma 8-epi-F₂ isoprostane concentrations were directly related only to TAOS at 90 min (r=-0.495, P=0.025). Stepwise multiple regression demonstrated that only TAOS at 90 min was independently and inversely related to peak plasma 8-epi-F₂ isoprostane (R²=0.248, P=0.025). Finally, the only variable independently inversely related to the absolute change in plasma 8-epi-F₂ isoprostane concentrations during the glucose tolerance test was TAOS at 90 min (r=-0.45, P=0.041), and when the upper tertile of the 8-epi-F₂ isoprostane increment was compared with the lower tertile, only TAOS at 90 min differed between tertiles (47.8± 10.4 vs. 62.9± 15.7%, respectively; P=0.023) (Table 2).

	CONCLUSIONS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
The main finding of this study is that acute hyperglycemia after a glucose load in type 2 diabetes is associated with an acute increase in plasma concentrations of 8-epi-F₂ isoprostane. This must indicate increased free radical–mediated generation of these compounds from arachidonic acid in membrane and lipoprotein phospholipids (8–12). This provides sensitive and direct evidence for a link between acute rather than chronic hyperglycemia and free radical damage in type 2 diabetes.

Changes in oxidative balance, or in antioxidant defenses, during acute hyperglycemia have been demonstrated before in subjects with and without type 2 diabetes (18–21). Increased LDL oxidizability induced by copper ions (22,23) has also been reported postprandially in type 2 diabetes, although the difficulties with this methodology have been reviewed (7), as has the confounding effect of dietary oxidized lipids (24). However, these measurements are surrogates, and the present study demonstrates directly increased plasma levels of a free radical–generated oxidation product of membrane arachidonic acid during acute hyperglycemia, independent of dietary intake of oxidized lipids or dietary isoprostane intake (25). Increased generation of reactive oxygen species is a feature of hyperglycemia in type 2 diabetes and impaired glucose tolerance (5,26), and the increased free radical damage during acute hyperglycemia demonstrated in this study occurred without significant changes in intracellular oxidative balance or plasma antioxidant capacity. That plasma total antioxidant capacity was the sole independent determinant of the increase in 8-epi-F₂ isoprostane may suggest that acute increases in free radical generation during hyperglycemia do not influence TAOS, but that it is limited by the variety of antioxidant defenses contributing to the TAOS measurements. It is also possible that the TAOS and GSH assays are less sensitive for detecting changes in oxidative balance or stress compared with the 8-epi-F₂ isoprostane assay used here, or that changes in TAOS and intracellular oxidative balance occurred before the 90-min sampling point used in this study.

Plasma F2 isoprostane concentrations increased by 34% during acute hyperglycemia, and this is similar to observations in other models of increased oxidative damage. For example, Morrow et al. (9) demonstrated increased plasma esterified 8-epi-F₂ isoprostane in heavy smokers, and smoking cessation led to a 24% reduction in mean 8-epi-F₂ isoprostane concentration within a few weeks. 8-Epi-F₂ isoprostane may also have biologically important proatherogenic actions, as well as being a marker for free radical damage. In vitro, 8-epi-F₂ isoprostane at physiological concentrations promotes increased message and protein for endothelin-1 (27), promotes platelet adhesion to collagen in a dose-dependent manner (28), and antagonizes some actions of nitric oxide (29). Also, increased levels of 8-epi-F₂ isoprostane are detectable in human coronary atherosclerotic plaque (29), particularly in smokers with increased oxidative damage rather than patients with treated hypertension or dyslipidemia (30), suggesting that 8-epi-F₂ isoprostane generation may occur within coronary plaque.

Metanalysis of available epidemiological and prospective studies has shown a consistent direct relationship between blood glucose levels and predominantly cardiovascular mortality (31) in type 2 diabetes, but some data suggest postprandial hyperglycemia may be an independent predictor of cardiovascular mortality in type 2 diabetes (1–3), and surrogates for macrovascular disease, such as carotid intimal-medial thickness, are more closely related to acute rather chronic hyperglycemia (32), and much of the controversy over the diagnostic classification of diabetes was based on the predictive power of post–glucose load hyperglycemia as a marker for increased vascular risk (33). The present data suggest one possible pathway for this association, by demonstrating increased free radical damage during acute hyperglycemia. This could promote an increase in vascular event rates through some of the mechanisms outlined above, or through proatherogenic processes sensitive to reactive oxygen species, such as increased adhesion molecule expression or coronary plaque metalloproteinase expression (34,35).

The present study demonstrates that acute hyperglycemia in type 2 diabetes is associated with a significant increase in free radical–mediated damage to membrane components, measured by plasma 8-epi-F₂ isoprostane concentrations, and this may be a link between acute hyperglycemia, increased free radical damage, and macrovascular risk in type 2 diabetes.

	Acknowledgments

 
We are grateful to Drs. Greenwood, Heyburn, and Temple for allowing access to their patients, and to the Norwich and Norfolk Diabetes Trust for funding salary costs associated with this project.

	Footnotes

 
Address correspondence and reprint requests to Dr. M.J. Sampson, Department of Endocrinology and Diabetes, Norfolk and Norwich University Hospital NHS Trust, Brunswick Rd., Norwich NR1 3SR, U.K. E-mail: mike.sampson{at}norfolk-norwich.thenhs.com.

Received for publication 25 July 2001 and accepted in revised form 30 November 2001.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

	References

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 

1. Hanefeld M, Julius U, Schmechel H, Schwanebeck U: Postprandial hyperglycemia is a risk factor for cardiovascular death in newly diagnosed type 2 diabetes: the Diabetes Intervention Study (DIS) (Abstract). Atherosclerosis 151 (Suppl. 1):1, 2000[Medline]
   
2. Balkau B, Bertrais S, Ducimetiere P, Eschwege E: Is there a glycemic threshold for mortality risk? Diabetes Care 22:696–699, 1999[Abstract/Free Full Text]
   
3. Balkau B, Eschwege E, Papoz L, Richard J-L, Claude J-R, Warnet J-M: Risk factors for early death in NIDDM and men with known glucose tolerance status. Br Med J 307:295–299, 1993
   
4. Lefebvre PJ, Scheen AJ: The postprandial state and risk of cardiovascular disease. Diabet Med 15 (Suppl. 4):S63–S68, 1998
   
5. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications (Review). Diabetes Care 3:257–267, 1996
   
6. Delmas-Beauvieux MC, Peuchant E, Thomas MJ: The place of electron spin resonance methods in the detection of oxidative stress in type 2 diabetes with poor glycemic control. Clin Biochem 31:221–228, 1998[Medline]
   
7. Halliwell B, Gutteridge JMC: Role of free radicals and catalytic metal ions in human disease an overview (Review). Methods Enzymol 186:1–85, 1990[Medline]
   
8. Morrow JD, Chen Y, Brame CJ, Yang J, Sanchez SC, Xu J, Zackert WE, Awad JA, Roberts LJ: The isoprostanes: unique prostaglandin like products of free radical initiate lipid peroxidation. Drug Metab Rev 31:117–139, 1999[Medline]
   
9. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ 2nd: Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med 332:1198–1203, 1995[Abstract/Free Full Text]
   
10. Barden A, Beilin LJ, Ritchie J, Croft KD, Walters BN, Michael CA: Plasma and urinary 8 isoprostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy. Clin Sci 91:711–718, 1996[Medline]
    
11. Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J: Plasma 8-epi-_{PGF 2} alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett225–229, 1995
    
12. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C: In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224–229, 1999[Abstract/Free Full Text]
    
13. Nemeth I, Boda D: The ratio of oxidised: reduced glutathione as an index of oxidative stress in various experimental models of shock syndrome. Biomed Biochim Acta 48:S53–S57, 1989[Medline]
    
14. Baker MA, Cerniglia GJ, Zaman A: Microtiter palate assay for the measurement of glutathione: and glutathione disulfide in large numbers of biological samples. Anal Biochem 190:360–365, 1990[Medline]
    
15. Nourooz-Zadeh J, Gopaul NK, Barrow S, Mallet AI, Anggard EE: Analysis Of F2-isoprostanes as indicators of nonezymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: development of a solid-phase extraction procedure. J Chromatogr B Biomed Appl 667:199–208, 1995[Medline]
    
16. Gopaul NK, Zacharowski K, Halliwell B, Änggård EE: Evaluation of the postprandial effects of a fast-food meal on human plasma F₂-isoprostane levels. Free Rad Biol Med 28:806–814, 2000[Medline]
    
17. Friedewald WT, Levy RI, Frederikson DS: Estimation of the concentration of LDL cholesterol: in plasma without the use of the preparative centrifuge. Clin Chem 18:499–502, 1972[Abstract]
    
18. Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A: Meal generated oxidative stress in type 2 diabetic patients. Diabetes Care 21:1529–1533, 1998[Abstract]
    
19. Ceriello A, Bortolotti N, Crescentini A: Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest 28:329–333, 1998[Medline]
    
20. Konukoglu D, Hatemi H, Ozer EM, Gonen S, Akcay T: The erythrocyte glutathione levels during oral glucose tolerance test. J Endocrinol Invest 20:471–475, 1998
    
21. Tessier D, Khalil A, Fulop T: Effects of an oral glucose challenge on free radicals/antioxidants balance in an older population with type II diabetes. Gerontol A Biol Sci Med Sci 54:M541–M545, 1999
    
22. Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Feletto F, Catone B, Taboga C: Meal induced oxidative stress and low density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 48:1503–1508, 1999[Medline]
    
23. Diwadkar VA, Anderson JW, Bridges SR, Gowri MS, Oelgten PR: Postprandial low density lipoproteins in type 2 diabetes are oxidised more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 222:178–184, 1999[Abstract/Free Full Text]
    
24. Staprans I, Hardman DA, Pan XM, Feingold KR: Effect of oxidised lipids in the diet on oxidised lipid levels in postprandial serum chylomicrons of diabetic patients. Diabetes Care 22:300–306, 1999[Abstract/Free Full Text]
    
25. Gopaul NK, Halliwell B, Anggard EE: Measurement f plasma F2-isoprostanes as an index f lipid peroxidation does not appear to be confounded by diet. Free Radic Res 33:115–127, 2000[Medline]
    
26. Laight DW, Carrier MJ, Anggard EE: Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev 15:274–282, 1999[Medline]
    
27. Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A: Free radical generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int 56:471–478, 1999[Medline]
    
28. Minuz P, Andrioli G, Degan M, Gaino S, Ortolani R, Tommasoli R, Zuliani V, Lechi A, Lechi C: The F2-isoprostane 8-epiprostaglandin F2alpha increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscler Thromb Vasc Biol 18:1248–1256, 1998[Abstract/Free Full Text]
    
29. Gniwotta C, Morrow JD, Roberts LJ, Kuhn H: Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 17:3236–3241, 1997[Abstract/Free Full Text]
    
30. Oguogho A, Karanikas G, Kritz H, Riehs G, Wagner O, Sinzinger H: 6-Oxo-PGF1alpha and 8-epi-_{PGF 2}alpha in human atherosclerotic vascular tissue. Prostaglandins Leukot Essent Fatty Acids 60:129–134, 1999[Medline]
    
31. Groeneveld Y, Petri H, Hermans J, Springer MP: Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med 16:12–13, 1999
    
32. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA_1c level. Diabetes Care 23:1830–1834, 2000[Abstract/Free Full Text]
    
33. DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617–621, 1994
    
34. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 92:1866–1874, 1993
    
35. Galis ZS, Asanuma K, Godin D, Meng X: N-acetyl-cysteine: decreases the matrix degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 97:2445–2453, 1998[Abstract/Free Full Text]
    

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				L. Monnier and C. Colette Glycemic Variability: Should we and can we prevent it? Diabetes Care, February 1, 2008; 31(Supplement_2): S150 - S154. [Abstract] [Full Text] [PDF]

				P. T.E. Wootton, N. L. Arora, F. Drenos, S. R. Thompson, J. A. Cooper, J. W. Stephens, S. J. Hurel, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, et al. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study Hum. Mol. Genet., June 15, 2007; 16(12): 1437 - 1444. [Abstract] [Full Text] [PDF]

				L. Mayahi, S. Heales, D. Owen, J. P. Casas, J. Harris, R. J. MacAllister, and A. D. Hingorani (6R)-5,6,7,8-Tetrahydro-L-Biopterin and Its Stereoisomer Prevent Ischemia Reperfusion Injury in Human Forearm Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1334 - 1339. [Abstract] [Full Text] [PDF]

				J. H.Y. Wu, N. C. Ward, A. P. Indrawan, C.-A. Almeida, J. M. Hodgson, J. M. Proudfoot, I. B. Puddey, and K. D. Croft Effects of {alpha}-Tocopherol and Mixed Tocopherol Supplementation on Markers of Oxidative Stress and Inflammation in Type 2 Diabetes Clin. Chem., March 1, 2007; 53(3): 511 - 519. [Abstract] [Full Text] [PDF]

				D. Sircar and P. V. Subbaiah Isoprostane Measurement in Plasma and Urine by Liquid Chromatography-Mass Spectrometry with One-Step Sample Preparation Clin. Chem., February 1, 2007; 53(2): 251 - 258. [Abstract] [Full Text] [PDF]

				A. Shamaei-Tousi, J. W. Stephens, R. Bin, J. A. Cooper, A. Steptoe, A. R.M. Coates, B. Henderson, and S. E. Humphries Association between plasma levels of heat shock protein 60 and cardiovascular disease in patients with diabetes mellitus Eur. Heart J., July 1, 2006; 27(13): 1565 - 1570. [Abstract] [Full Text] [PDF]

				L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J.-P. Cristol, and C. Colette Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes JAMA, April 12, 2006; 295(14): 1681 - 1687. [Abstract] [Full Text] [PDF]

				J. W. Stephens, D. R. Gable, S. J. Hurel, G. J. Miller, J. A. Cooper, and S. E. Humphries Increased Plasma Markers of Oxidative Stress Are Associated with Coronary Heart Disease in Males with Diabetes Mellitus and with 10-Year Risk in a Prospective Sample of Males Clin. Chem., March 1, 2006; 52(3): 446 - 452. [Abstract] [Full Text] [PDF]

				P. T.E. Wootton, F. Drenos, J. A. Cooper, S. R. Thompson, J. W. Stephens, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, and P. J. Talmud Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study Hum. Mol. Genet., January 15, 2006; 15(2): 355 - 361. [Abstract] [Full Text] [PDF]

				B. Manuel-y-Keenoy, A. Van Campenhout, P. Aerts, J. Vertommen, P. Abrams, L. F. Van Gaal, C. Van Gils, and I. H. De Leeuw Time Course of Oxidative Stress Status in the Postprandial and Postabsorptive States in Type 1 Diabetes Mellitus: Relationship to Glucose and Lipid Changes J. Am. Coll. Nutr., December 1, 2005; 24(6): 474 - 485. [Abstract] [Full Text] [PDF]

				R. H Boger, E. Schwedhelm, R. Maas, S. Quispe-Bravo, and C. Skamira ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study Vascular Medicine, July 1, 2005; 10(1_suppl): S97 - S102. [Abstract] [PDF]

				R. H Boger, E. Schwedhelm, R. Maas, S. Quispe-Bravo, and C. Skamira ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study Vascular Medicine, May 1, 2005; 10(2_suppl): S97 - S102. [Abstract] [PDF]

				E. Pagnin, G. Fadini, R. de Toni, A. Tiengo, L. Calo, and A. Avogaro Diabetes Induces p66shc Gene Expression in Human Peripheral Blood Mononuclear Cells: Relationship to Oxidative Stress J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1130 - 1136. [Abstract] [Full Text] [PDF]

				B. R. Clapp, A. D. Hingorani, R. K. Kharbanda, V. Mohamed-Ali, J. W. Stephens, P. Vallance, and R. J. MacAllister Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress Cardiovasc Res, October 1, 2004; 64(1): 172 - 178. [Abstract] [Full Text] [PDF]

				A. M. Vincent, J. W. Russell, P. Low, and E. L. Feldman Oxidative Stress in the Pathogenesis of Diabetic Neuropathy Endocr. Rev., August 1, 2004; 25(4): 612 - 628. [Abstract] [Full Text] [PDF]

				W.-m. R. Wong, J. W. Stephens, J. Acharya, S. J. Hurel, S. E. Humphries, and P. J. Talmud The APOA4 T347S variant is associated with reduced plasma TAOS in subjects with diabetes mellitus and cardiovascular disease J. Lipid Res., August 1, 2004; 45(8): 1565 - 1571. [Abstract] [Full Text] [PDF]

				M. T. Coughlan, M. Permezel, H. M. Georgiou, and G. E. Rice Repression of Oxidant-Induced Nuclear Factor-{kappa}B Activity Mediates Placental Cytokine Responses in Gestational Diabetes J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3585 - 3594. [Abstract] [Full Text] [PDF]

				S. S Dhamrait, J. W Stephens, J. A Cooper, J. Acharya, A. R Mani, K. Moore, G. J Miller, S. E Humphries, S. J Hurel, and H. E Montgomery Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2 Eur. Heart J., March 2, 2004; 25(6): 468 - 475. [Abstract] [Full Text] [PDF]

				H. Urakawa, A. Katsuki, Y. Sumida, E. C. Gabazza, S. Murashima, K. Morioka, N. Maruyama, N. Kitagawa, T. Tanaka, Y. Hori, et al. Oxidative Stress Is Associated with Adiposity and Insulin Resistance in Men J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4673 - 4676. [Abstract] [Full Text] [PDF]

				N. Ihlemann, C. Rask-Madsen, A. Perner, H. Dominguez, T. Hermann, L. Kober, and C. Torp-Pedersen Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H875 - H882. [Abstract] [Full Text] [PDF]

				A. Katsuki, Y. Sumida, H. Urakawa, E. C. Gabazza, N. Maruyama, K. Morioka, N. Kitagawa, Y. Hori, K. Nakatani, Y. Yano, et al. Increased Oxidative Stress Is Associated With Elevated Plasma Levels of Adrenomedullin in Hypertensive Patients With Type 2 Diabetes Diabetes Care, May 1, 2003; 26(5): 1642 - 1643. [Full Text] [PDF]

				T. Tsunekawa, T. Hayashi, Y. Suzuki, H. Matsui-Hirai, H. Kano, A. Fukatsu, N. Nomura, A. Miyazaki, and A. Iguchi Plasma Adiponectin Plays an Important Role in Improving Insulin Resistance With Glimepiride in Elderly Type 2 Diabetic Subjects Diabetes Care, February 1, 2003; 26(2): 285 - 289. [Abstract] [Full Text] [PDF]

				U. Riserus, S. Basu, S. Jovinge, G. N. Fredrikson, J. Arnlov, and B. Vessby Supplementation With Conjugated Linoleic Acid Causes Isomer-Dependent Oxidative Stress and Elevated C-Reactive Protein: A Potential Link to Fatty Acid-Induced Insulin Resistance Circulation, October 8, 2002; 106(15): 1925 - 1929. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar